Citi keeps USD 325 target for Jazz Pharmaceuticals stock

Published on 10/18/2026 at 13:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Citi kept its Buy rating and USD 325.00 target on October 15, 2026. Second-quarter revenue reached USD 1.21 billion, up 15.50 percent year over year.

Analyst signal and operating scale

Citi maintained a Buy rating and a USD 325.00 target on October 15, 2026.
Second-quarter 2026 revenue reached USD 1.21 billion, up 15.50 percent year over year.
Twenty analysts carried a USD 291.25 average 12-month target in an October 15, 2026 overview.

JAZZ, IE00B4Q5ZN47, Illustration mit AI erstellt.

Jazz Pharmaceuticals (IE00B4Q5ZN47) drew a USD 325.00 price target from Citi on October 15, 2026, while the bank maintained its Buy rating, Markets Insider reported. The signal followed second-quarter revenue of USD 1.21 billion, which rose 15.50 percent year over year, according to MarketBeat.

Revenue growth meets an earnings test

Jazz reported USD 1.21 billion in revenue for the second quarter of 2026, compared with USD 1.11 billion expected by analysts. The 15.50 percent year-over-year increase therefore came with a clear comparison point, but adjusted earnings per share of USD 5.71 fell short of the USD 6.18 consensus estimate, MarketBeat reported.

What does the target say about valuation?

Citi's USD 325.00 target sits above the broader USD 291.25 average 12-month target from 20 analysts listed by MarketBeat on October 15, 2026. The overview counted 18 Buy ratings, one Hold and one Strong Buy, giving the latest target action a more constructive tone than the aggregate view.

Three dated milestones shape the story

On August 3, 2026, Jazz reported USD 1.21 billion in quarterly revenue and adjusted earnings per share of USD 5.71, according to MarketBeat. On September 15, 2026, the company completed its Actio Biosciences acquisition for USD 820 million, according to Simplify. On October 15, 2026, Citi maintained its Buy rating and set the USD 325.00 target, Markets Insider reported.

Stock context for investors

The latest analyst action leaves revenue growth and earnings conversion as the central balance. Jazz's second-quarter operating margin was 21.00 percent, while diluted earnings per share were USD 2.78, based on the second-quarter 2026 financial statement. For investors, the gap between USD 5.71 adjusted earnings per share and USD 6.18 consensus is the immediate counterweight to the revenue increase.

The further course of trading is shown by the continuously updated real-time quote of Jazz Pharmaceuticals stock.